


## IN THE CLAIMS

This is a complete and current listing of the claims, marked with status identifiers in parentheses. The following listing of claims will replace all prior versions and listings of claims in the application.

### Claims

1. (Previously Presented) A compound of the following general formula (I):



(I)

wherein

$R_2$  designates hydrogen, Me, Et, CHO, CN, OH, OMe,  $COR_9$ ,  $COOR_9$ ,  $CONHR_9$  or  $CSNHR_9$ , whereby  $R_9$  denotes  $(C_1-C_4)$  alkyl;

$R_5$  designates hydrogen,  $(C_1-C_4)$  alkyl, OH,  $(C_1-C_4)$  alkoxy,  $OCF_3$ , trifluoromethyl or halogen;

$R_6$  designates Me,  $(C_1-C_4)$  alkoxy,  $OCF_3$ , SMe or SEt;

$n$  is 1 or 2;

R<sub>3</sub>' and R<sub>5</sub>' each independently designate OH, Me, Et, OMe, OCF<sub>3</sub>, trifluoromethyl or halogen;

U designates N or CR<sub>2</sub>', whereby R<sub>2</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen;

V designates N or CR<sub>4</sub>', whereby R<sub>4</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, (C<sub>1</sub>-C<sub>6</sub>) alkyl, OH, trifluoromethyl or halogen;

W designates N or CR<sub>6</sub>', whereby R<sub>6</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen; and pharmaceutically acceptable salts thereof.

2. (Previously Presented) A compound according to claim 1, wherein R<sub>2</sub> designates Me, OH, CN, CHO, COR<sub>9</sub> or COOR<sub>9</sub>.

3. (Previously Presented) A compound according to claim 1, wherein R<sub>2</sub> designates Me, CN, CHO or COMe.

4. (Currently Amended) A compound according to ~~one of claims 1 to 3, wherein~~ wherein R<sub>5</sub> designates hydrogen, Me, OMe or halogen.

5. (Currently Amended) A compound according to ~~one of claims 1 to 4, wherein~~ R<sub>6</sub> designates OMe or OEt.

6. (Currently Amended) A compound according to ~~one of claims 1 to 3, wherein~~ R<sub>5</sub> designates hydrogen or OMe, preferably hydrogen; and R<sub>6</sub> designates OMe.

7. (Currently Amended) A compound according to ~~one of claims 1 to 6, wherein~~ R<sub>3</sub>' and R<sub>5</sub>' each independently designate chloro, bromo, Me or OMe.

8. (Currently Amended) A compound according to claim 1 ~~to 7, wherein~~ R<sub>3</sub>' and R<sub>5</sub>' are identical; or R<sub>3</sub>' designates chloro or bromo, and R<sub>5</sub>' designates OMe.

9. (Previously Presented) A compound according to claim 7, wherein R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

10. (Currently Amended) A compound according to ~~one of~~ claims 1 to 9, wherein U and W designate CH and V designates CR<sub>4</sub>'.

11. (Previously Presented) A compound according to claim 10, wherein R<sub>4</sub>' designates hydrogen, chloro, bromo, Me or OMe.

12. (Previously Presented) A compound according to claim 10, wherein R<sub>3</sub>', R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>3</sub>' designates chloro and R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>4</sub>' designates hydrogen and R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

13. (Previously Presented) A compound according to claim 1, which is 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-

tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-  
tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-

tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, or a pharmaceutically acceptable salt thereof.

14. (Currently Amended) A compound according to ~~any one of claims 1 to 13~~, which is the (R) - or (S)-enantiomer.

15. (Currently Amended) A compound as defined in ~~one of claims 1 to 14~~, for use as a medicament.

16. (Currently Amended) Use of a compound as defined in ~~one of claims 1 to 14~~, for the preparation of a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial.

17. (Previously Presented) The use according to claim 16, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

18. (Currently Amended) A method of treatment or prophylaxis of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in need of such treatment or prophylaxis, comprising administering to

said subject an amount of a compound (I) as defined in ~~one of claims 1 to 14~~ in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

19. (Previously Presented) The method of claim 18, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

20. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 14~~, and a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (Currently Amended) Articles containing a compound of the formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any one of claims 1 to 14~~, and a chemotherapeutic agent, as a combination for the simultaneous, separate or successive administration in the therapy of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial.

22. (Currently Amended) Use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any of claims 1 to 14~~, as a pharmacological tool in the development and standardization of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals.